{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:28:39Z","timestamp":1791242919222,"version":"4.1.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":122,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"name":"German Diabetes Center"},{"name":"German Federal Ministry of Health"},{"name":"German Center for Diabetes Research"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate whether the sodium\u2013glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Patients with T2D (n = 84) (HbA1c 6.6 \u00b1 0.5% [49 \u00b1 10 mmol\/mol], known disease duration 39 \u00b1 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnetic resonance methods from 0 (baseline) to 24 weeks between groups. Tissue-specific insulin sensitivity (secondary outcome) was assessed by two-step clamps using an isotope dilution technique. Exploratory analysis comprised circulating surrogate markers of insulin sensitivity and liver function. Statistical comparison was done by ANCOVA adjusted for respective baseline values, age, sex, and BMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>EMPA treatment resulted in a placebo-corrected absolute change of \u22121.8% (95% CI \u22123.4, \u22120.2; P = 0.02) and relative change in LFC of \u221222% (\u221236, \u22127; P = 0.009) from baseline to end of treatment, corresponding to a 2.3-fold greater reduction. Weight loss occurred only with EMPA (placebo-corrected change \u22122.5 kg [\u22123.7, \u22121.4]; P &amp;lt; 0.001), while no placebo-corrected change in tissue-specific insulin sensitivity was observed. EMPA treatment also led to placebo-corrected changes in uric acid (\u221274 mol\/L [\u2212108, \u221242]; P &amp;lt; 0.001) and high-molecular-weight adiponectin (36% [16, 60]; P &amp;lt; 0.001) levels from 0 to 24 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc19-0641","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T10:14:06Z","timestamp":1568974446000},"page":"298-305","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":331,"title":["Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial"],"prefix":"10.2337","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02637973","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"given":"Sabine","family":"Kahl","sequence":"first","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Gancheva","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Stra\u00dfburger","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-093X","authenticated-orcid":false,"given":"Christian","family":"Herder","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Machann","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich at the University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Katsuyama","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6455-3769","authenticated-orcid":false,"given":"Stefan","family":"Kabisch","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbr\u00fccke, Nuthetal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Henkel","sequence":"additional","affiliation":[{"name":"Clinical Study Center of Metabolic Vascular Medicine, GWT-TUD GmbH, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kopf","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Department of Internal Medicine 1 and Clinical Chemistry, University Hospital of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit","family":"Lagerpusch","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbr\u00fccke, Nuthetal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kantartzis","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich at the University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Kupriyanova","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Markgraf","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"van Gemert","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Knebel","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin F.","family":"Wolkersdorfer","sequence":"additional","affiliation":[{"name":"Landesapotheke Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-5869","authenticated-orcid":false,"given":"Oliver","family":"Kuss","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hee","family":"Hwang","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan R.","family":"Bornstein","sequence":"additional","affiliation":[{"name":"Paul Langerhans Institute Dresden, Helmholtz Center Munich at University Hospital MKIII, and Faculty of Medicine, TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kasperk","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Department of Internal Medicine 1 and Clinical Chemistry, University Hospital of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-9595","authenticated-orcid":false,"given":"Norbert","family":"Stefan","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich at the University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbr\u00fccke, Nuthetal, Germany"},{"name":"Department of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Charit\u00e9 University Medicine, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-9023","authenticated-orcid":false,"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6382","authenticated-orcid":false,"given":"Michael","family":"Roden","sequence":"additional","affiliation":[{"name":"Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, D\u00fcsseldorf, Germany"},{"name":"German Center for Diabetes Research, M\u00fcnchen-Neuherberg, Germany"},{"name":"Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"2022031300180083600_B1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022031300180083600_B2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300180083600_B3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-016-3941-4","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects","volume":"59","author":"Toplak","year":"2016","journal-title":"Diabetologia"},{"key":"2022031300180083600_B4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"2022031300180083600_B5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2022031300180083600_B6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300180083600_B7","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300180083600_B8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022031300180083600_B9","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"2022031300180083600_B10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter","year":"2016","journal-title":"Diabetes Metab"},{"key":"2022031300180083600_B11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"2022031300180083600_B12","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes\u20142014","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031300180083600_B13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mrm.20825","article-title":"Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy","volume":"55","author":"Machann","year":"2006","journal-title":"Magn Reson Med"},{"key":"2022031300180083600_B14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jmri.20831","article-title":"Water-fat separation with IDEAL gradient-echo imaging","volume":"25","author":"Reeder","year":"2007","journal-title":"J Magn Reson Imaging"},{"key":"2022031300180083600_B15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jmri.22036","article-title":"Topography mapping of whole body adipose tissue using A fully automated and standardized procedure","volume":"31","author":"W\u00fcrslin","year":"2010","journal-title":"J Magn Reson Imaging"},{"key":"2022031300180083600_B16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1148\/radiol.10092284","article-title":"Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes","volume":"257","author":"Machann","year":"2010","journal-title":"Radiology"},{"key":"2022031300180083600_B17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/dom.12112","article-title":"Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes","volume":"15","author":"Phielix","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031300180083600_B18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/ajcn\/36.5.936","article-title":"A short questionnaire for the measurement of habitual physical activity in epidemiological studies","volume":"36","author":"Baecke","year":"1982","journal-title":"Am J Clin Nutr"},{"key":"2022031300180083600_B19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00125-014-3457-8","article-title":"Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial","volume":"58","author":"Nowotny","year":"2015","journal-title":"Diabetologia"},{"key":"2022031300180083600_B20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300180083600_B21","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031300180083600_B22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cgh.2008.07.013","article-title":"Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials","volume":"6","author":"Loomba","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022031300180083600_B23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022031300180083600_B24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"Hazlehurst","year":"2016","journal-title":"Metabolism"},{"key":"2022031300180083600_B25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022031300180083600_B26","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s00125-018-4630-2","article-title":"Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME\u00ae","volume":"61","author":"Zinman","year":"2018","journal-title":"Diabetologia"},{"key":"2022031300180083600_B27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"2022031300180083600_B28","doi-asserted-by":"crossref","DOI":"10.1002\/9780470513095","volume-title":"Clinical Diabetes Research: Methods and Techniques","author":"Roden","year":"2007"},{"key":"2022031300180083600_B29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"key":"2022031300180083600_B30","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/db16-1410","article-title":"Correcting postprandial hyperglycemia in Zucker diabetic fatty rats with an SGLT2 inhibitor restores glucose effectiveness in the liver and reduces insulin resistance in skeletal muscle","volume":"66","author":"O\u2019Brien","year":"2017","journal-title":"Diabetes"},{"key":"2022031300180083600_B31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031300180083600_B32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031300180083600_B33","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes"},{"key":"2022031300180083600_B34","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry","year":"2019","journal-title":"Nat Commun"},{"key":"2022031300180083600_B35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diabetes.48.5.1198","article-title":"Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo","volume":"48","author":"Cherrington","year":"1999","journal-title":"Diabetes"},{"key":"2022031300180083600_B36","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","author":"Lai","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2022031300180083600_B37","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2337\/db12-1814","article-title":"Sugar, uric acid, and the etiology of diabetes and obesity","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"key":"2022031300180083600_B38","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"2022031300180083600_B39","doi-asserted-by":"crossref","first-page":"e0194127","DOI":"10.1371\/journal.pone.0194127","article-title":"Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses","volume":"13","author":"Bellou","year":"2018","journal-title":"PLoS One"},{"key":"2022031300180083600_B40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1037\/1082-989X.7.2.147","article-title":"Missing data: our view of the state of the art","volume":"7","author":"Schafer","year":"2002","journal-title":"Psychol Methods"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-0641","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/2\/298\/531409\/dc190641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/2\/298\/531409\/dc190641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T22:30:42Z","timestamp":1647124242000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/2\/298\/36104\/Empagliflozin-Effectively-Lowers-Liver-Fat-Content"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,20]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-0641","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]}}}